SUBMISSION BY THE UNITED STATES OF AMERICA

The following submission, received on 2 July 2025, is the statement made by the United States of America at the 18-19 June 2025 WTO SPS Committee, and is being circulated at the request of the Delegation of the United States of America.

_______________

1.  The United States remains concerned that the European Union's implementation of Article 118 will result in unnecessary negative trade impacts to US exports.

2.  The European Union still has not provided a risk assessment to support the restriction of certain products derived from animals treated with antimicrobials.

3.  Furthermore, the European Union has yet to clarify its rationale regarding restrictions on the use of non-medically important antimicrobials to promote growth.

4.  As such, Article 118 does not appear to address the issue of anti-microbial resistance (AMR) from a science- and risk-based standpoint, nor does it appear to be consistent with existing international guidance on combatting AMR.

5.  We look forward to continuing engagement with the European Union and other trading partners on mitigating the potential for any trade disruptions resulting from the implementation of Article 118.